Drug Trial Radar · NCT06757504
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 13, 2025
Primary completion
Feb 6, 2026
Study completion May 8, 2026
Sponsor
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
Conditions
- Autism Spectrum Disorder (ASD)
Interventions
TTYP01 Tablets (12mg or 18mg)Drug
Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Placebo (Simulant TTYP01 Tablets)Drug
Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal) scores at Week 12.Time frame: At baseline and week 12
- Incidence and severity of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and TEAEs that lead to treatment discontinuation.Time frame: Throughout the trial period
- Plasma concentrations and population PK profiles of edaravone and its metabolites in adolescent and pediatric ASD participants.Time frame: Visit 2 (Day 1): 30 minutes (±5 minutes) and 3 hours (±10 minutes) after the first dose; Visit 8 (Week 12 ±2 Days)or Early withdrawal: before the first dose (0 hour), and 30 minutes (±5 minutes) after the first dose on the day of the visit.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Peking University Sixth Hospital
Beijing, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, China · Not yet recruiting
Nanjing Brain Hospital, The Affiliated Brain Hospital of Nanjing Medical University
Nanjing, China · Not yet recruiting
Tianjin Mental Health Center
Tianjin, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.